Post-eradication poliovirus facility-associated community risks

被引:13
|
作者
Dowdle, Walter R.
Wolff, Chris
机构
[1] Task Force Child Survial & Dev, Decatur, GA 30030 USA
[2] WHO, Vaccine Assessment & Monitoring, CH-1211 Geneva 27, Switzerland
关键词
poliovirus containment; community risks; transmission risks; laboratory containment;
D O I
10.1016/j.biologicals.2006.03.003
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Minimizing the risk of poliovirus transmission from the poliovirus facility to an increasingly susceptible community is crucial when global poliovirus transmission and OPV use stops. Community risks of exposure to wild poliovirus as well as Sabin strains are highest from facility personnel who are unknowingly contaminated or infected. Immunization with OPV or IPV prevents poliomyelitis, but neither vaccine fully inhibits silent infection of the gut. Facility environments maintained at low relative humidity (< 50%) may reduce poliovirus survival and inhalation risk. Circulating antibodies reduce personnel infection risks from injection or virus entry through breaks in skin or mucous membranes. Community exposure risk through inhalation of contaminated air effluent is likely low in most modern facilities. Community risks through ingestion of liquid effluents are facility-specific and may range from high to low. This assessment of community risks, when combined with assessments of facility-specific hazards and the consequences of wild or Sabin poliovirus transmission, provides the foundation for effective risk management. (c) 2006 The International Association for Biologicals. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:127 / 132
页数:6
相关论文
共 50 条
  • [31] Healthcare Facility-Associated Clostridium difficile Infection in Solid Organ Transplant Recipients
    Donnelly, J.
    Wang, H.
    Locke, J.
    Mannon, R.
    Baddley, J.
    TRANSPLANTATION, 2014, 98 : 772 - 772
  • [32] Healthcare Facility-Associated Clostridium difficile Infection in Solid Organ Transplant Recipients
    Donnelly, J.
    Wang, H.
    Locke, J.
    Mannon, R.
    Baddley, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 772 - 772
  • [33] Perspective: Determinants of the severity of poliovirus outbreaks in the post eradication era
    Fine, P. E. M.
    Ritchie, S.
    RISK ANALYSIS, 2006, 26 (06) : 1533 - 1540
  • [34] The feasibility of identifying children with primary immunodeficiency disorders: Preparation for the polio post-eradication era in Bangladesh
    Sazzad, Hossain M. S.
    Rainey, Jeanette J.
    Mach, Ondrej
    Sutter, Roland
    Diordista, Serguei
    Kawser, Choudhury A.
    Mobarak, Reaz
    Alam, Didarul
    Chowdhury, Mahmood A.
    Hossain, M. Jahangir
    Hasan, A. S. M. Mainul
    Luby, Stephen P.
    VACCINE, 2012, 30 (36) : 5396 - 5400
  • [35] Modelling the expected rate of laboratory biosafety breakdowns involving rinderpest virus in the post-eradication era
    Beauvais, W.
    Fournie, G.
    Jones, B. A.
    Cameron, A.
    Njeumi, F.
    Lubroth, J.
    Pfeiffer, D. U.
    PREVENTIVE VETERINARY MEDICINE, 2013, 112 (3-4) : 248 - 256
  • [36] Evaluating the effectiveness & costs of strategies post-eradication to monitor for freedom from BVDV infection in Ireland
    Brock, Jonas
    Guelbenzu-Gonzalo, Maria
    Lange, Martin
    Tratalos, Jamie A.
    Barrett, Damien
    Lane, Liz
    More, Simon J.
    Graham, David A.
    Thulke, Hans-Hermann
    AGRICULTURAL SYSTEMS, 2024, 221
  • [37] Apropos risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis
    Arya, Subhash C.
    Agarwal, Nirmala
    EXPERT REVIEW OF VACCINES, 2012, 11 (11) : 1291 - 1291
  • [38] HELICOBACTER-PYLORI CAUSES HYPERPROLIFERATION OF THE GASTRIC EPITHELIUM - PRE-ERADICATION AND POST-ERADICATION INDEXES OF PROLIFERATING CELL NUCLEAR ANTIGEN
    BRENES, F
    RUIZ, B
    CORREA, P
    HUNTER, F
    RHAMAKRISHNAN, T
    FONTHAM, E
    SHI, TY
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1993, 88 (11): : 1870 - 1875
  • [39] Economics of polio vaccination in the post-eradication era: Should OPV-using countries adopt IPV?
    Khan, M. Mahmud
    VACCINE, 2008, 26 (16) : 2034 - 2040
  • [40] Progress in the Development of Poliovirus Antiviral Agents and Their Essential Role in Reducing Risks That Threaten Eradication
    McKinlay, Mark A.
    Collett, Marc S.
    Hincks, Jeffrey R.
    Oberste, M. Steven
    Pallansch, Mark A.
    Okayasu, Hiromasa
    Sutter, Roland W.
    Modlin, John F.
    Dowdle, Walter R.
    JOURNAL OF INFECTIOUS DISEASES, 2014, 210 : S447 - S453